Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

377
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
377
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

315
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
315
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Design of the OverCool study: Lung-conservative liquid ventilation for the induction of Ultra-Rapid Cooling after Cardiac Arrest (OverCool).

Resuscitation plus·2025
Same author

Association of age with extubation failure in neurocritical intensive care unit patients--Insight from an international prospective study named ENIO.

Journal of critical care·2025
Same author

A consensus of European experts on the definition of ventilator-associated pneumonia recurrences obtained by the Delphi method: the RECUVAP study.

Intensive care medicine·2025
Same author

Recovery Potential in Patients After Cardiac Arrest Who Die After Limitations or Withdrawal of Life Support.

JAMA network open·2025
Same author

Alterations in the renin-angiotensin system during septic shock.

Annals of intensive care·2025
Same author

Management of severe acute encephalopathy in the ICU: an expert consensus statement from the french society of intensive care medicine.

Annals of intensive care·2025
Same journal

Mouse models to study von Willebrand factor in inflammation: a scoping review.

Intensive care medicine experimental·2026
Same journal

Confocal laser endomicroscopy in patients with acute respiratory failure.

Intensive care medicine experimental·2026
Same journal

Source-controlled bacterial peritonitis improves survival but leaves persistent lung inflammation and airway IgA loss.

Intensive care medicine experimental·2026
Same journal

Noradrenaline-trajectory phenotypes in septic shock: derivation and external validation in two independent cohorts.

Intensive care medicine experimental·2026
Same journal

Exploratory dose modeling of hemoadsorption in pediatric septic shock.

Intensive care medicine experimental·2026
Same journal

Sex-related differences in lung injury distribution and outcomes in COVID-19 acute respiratory failure: insights from the CT-COVID19 multicenter study group.

Intensive care medicine experimental·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Sep 9, 2025

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

18.4K

La administración de dobutamina: una propuesta para un enfoque estandarizado

Lorenzo Calabró1, Filippo Annoni2, Fabio Silvio Taccone2

  • 1Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, 1070, Brussels, Belgium. l.calabro@hubruxelles.be.

Intensive care medicine experimental
|August 31, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Este estudio propone un marco para el uso de dobutamina, un agente inotrópico, en pacientes en estado crítico. Hace hincapié en las indicaciones claras y el monitoreo continuo para optimizar la contractilidad cardíaca y mejorar los resultados de los pacientes.

Palabras clave:
Producción cardíacaDobutamina y sus derivadosMonitoreo hemodinámicoDisfunción de órganosEl choquePerfusión de tejidos

Más Videos Relacionados

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

18.4K
Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Área de la Ciencia:

  • Medicina de cuidados intensivos
  • Cardiología
  • Farmacología

Sus antecedentes:

  • La dobutamina es un agente inotrópico común para pacientes en estado crítico con contractilidad cardíaca alterada.
  • Su perfil de beneficio-riesgo es objeto de debate, y carece de orientación estructurada para su uso.

Objetivo del estudio:

  • Proponer un marco pragmático para la administración de dobutamina en contextos clínicos y experimentales.
  • Asegurar el uso racional y consistente de dobutamina en el choque con bajo rendimiento cardíaco, incluido el choque cardiogénico, el choque séptico y el síndrome de bajo rendimiento cardíaco (LCOS).

Principales métodos:

  • La dobutamina debe prescribirse para la insuficiencia circulatoria aguda con hipoperfusión y deterioro de la contractilidad cardíaca; el índice cardíaco bajo por sí solo es insuficiente.
  • La ecocardiografía es crucial para la evaluación inicial, complementada por el monitoreo continuo del rendimiento cardíaco para la evaluación de la relación dosis-respuesta.
  • Un enfoque estandarizado implica una dosis inicial de 2,5 μg/kg/min con una titulación gradual basada en el índice cardíaco y los marcadores de perfusión cada 20 minutos.

Principales resultados:

  • La escalada de la dosis de dobutamina debe guiarse por un aumento significativo del índice cardíaco y la resolución de la hipoperfusión.
  • La hipoperfusión persistente a pesar de la mejora del índice cardíaco sugiere una respuesta inadecuada, lo que justifica un aumento de la dosis con precaución.
  • La hipoperfusión continuada con un aumento adicional del índice cardíaco indica un déficit independiente del flujo, lo que desalienta una mayor titulación.

Conclusiones:

  • El uso de dobutamina requiere indicaciones claras y un enfoque estandarizado que integre el monitoreo hemodinámico y de perfusión continuo.
  • Esta estrategia tiene como objetivo optimizar los beneficios terapéuticos y minimizar la exposición innecesaria y los efectos adversos.
  • El marco propuesto promueve la terapia inotrópica racional y reproducible en centros de cuidados intensivos.